Correlation Between Cadrenal Therapeutics, and Lineage Cell
Can any of the company-specific risk be diversified away by investing in both Cadrenal Therapeutics, and Lineage Cell at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cadrenal Therapeutics, and Lineage Cell into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Cadrenal Therapeutics, Common and Lineage Cell Therapeutics, you can compare the effects of market volatilities on Cadrenal Therapeutics, and Lineage Cell and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cadrenal Therapeutics, with a short position of Lineage Cell. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cadrenal Therapeutics, and Lineage Cell.
Diversification Opportunities for Cadrenal Therapeutics, and Lineage Cell
-0.16 | Correlation Coefficient |
Good diversification
The 3 months correlation between Cadrenal and Lineage is -0.16. Overlapping area represents the amount of risk that can be diversified away by holding Cadrenal Therapeutics, Common and Lineage Cell Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lineage Cell Therapeutics and Cadrenal Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cadrenal Therapeutics, Common are associated (or correlated) with Lineage Cell. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lineage Cell Therapeutics has no effect on the direction of Cadrenal Therapeutics, i.e., Cadrenal Therapeutics, and Lineage Cell go up and down completely randomly.
Pair Corralation between Cadrenal Therapeutics, and Lineage Cell
Given the investment horizon of 90 days Cadrenal Therapeutics, Common is expected to generate 0.76 times more return on investment than Lineage Cell. However, Cadrenal Therapeutics, Common is 1.31 times less risky than Lineage Cell. It trades about -0.03 of its potential returns per unit of risk. Lineage Cell Therapeutics is currently generating about -0.15 per unit of risk. If you would invest 1,509 in Cadrenal Therapeutics, Common on August 29, 2024 and sell it today you would lose (138.00) from holding Cadrenal Therapeutics, Common or give up 9.15% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Cadrenal Therapeutics, Common vs. Lineage Cell Therapeutics
Performance |
| Timeline |
| Cadrenal Therapeutics, |
| Lineage Cell Therapeutics |
Cadrenal Therapeutics, and Lineage Cell Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Cadrenal Therapeutics, and Lineage Cell
The main advantage of trading using opposite Cadrenal Therapeutics, and Lineage Cell positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cadrenal Therapeutics, position performs unexpectedly, Lineage Cell can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lineage Cell will offset losses from the drop in Lineage Cell's long position.| Cadrenal Therapeutics, vs. Eliem Therapeutics | Cadrenal Therapeutics, vs. Scpharmaceuticals | Cadrenal Therapeutics, vs. Milestone Pharmaceuticals | Cadrenal Therapeutics, vs. Seres Therapeutics |
| Lineage Cell vs. MAIA Biotechnology | Lineage Cell vs. Armata Pharmaceuticals | Lineage Cell vs. Portage Biotech | Lineage Cell vs. Cadrenal Therapeutics, Common |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Complementary Tools
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |